Cyclo Therapeutics
CYTH
Market cap $19.5M

0.6810 USD

-0.0390

5.42%

At close Nov 19, 4:00 PM EST

1 day

-5.42%

5 days

-5.42%

1 month

-15.93%

3 months

-45.08%

6 months

-52.04%

Year to date

-58.98%

1 year

-49.93%

5 years

-83.79%

10 years

-83.79%

About: Cyclo Therapeutics Inc is a clinical-stage biotechnology firm. The company is engaged in developing cyclodextrin-based products for treating neurodegenerative diseases, particularly Niemann-Pick Type C disease (NPC). The company's lead drug candidate, Trappsol Cyclo, has undergone clinical trials for NPC treatment. Operating in one segment, the company focuses on developing and commercializing cyclodextrin-based treatments for rare diseases. Revenue primarily comes from selling cyclodextrins and related products to pharmaceutical and nutritional industries, with Trappsol HPB and Trappsol Fine Chemical being significant contributors.

Employees: 8

Healthcare Biological Products, Except Diagnostic Substances

0

Funds holding %

of 6,735 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

75% more repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 4

0.12% more ownership

Funds ownership: 7.82% [Q2] → 7.94% (+0.12%) [Q3]

0% more funds holding in top 10

Funds holding in top 10: 2 [Q2] → 2 (+0) [Q3]

14% less funds holding

Funds holding: 22 [Q2] → 19 (-3) [Q3]

19% less capital invested

Capital invested by funds: $2.84M [Q2] → $2.3M (-$541K) [Q3]

75% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 4

See Fund Rankings

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$0.95

40%

upside

Avg. target

$0.95

40%

upside

High target

$0.95

40%

upside

2 analyst ratings

1 positive

50%

1 neutral

50%

0 negative

0%

Ascendiant Capital Lucas Ward 11% 1-year accuracy 1 / 9 met price target	40%upside $0.95	Buy Maintained	26 Aug 2024
HC Wainwright & Co. Swayampakula Ramakanth 25% 1-year accuracy 35 / 140 met price target	40%upside $0.95	Neutral Downgraded	23 Aug 2024

See Analyst Rankings

Financial journalist opinion

Zacks Investment Research

Cyclo Therapeutics, Inc. (CYTH) Reports Q3 Loss, Lags Revenue Estimates

Cyclo Therapeutics, Inc. (CYTH) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to loss of $0.29 per share a year ago.

Cyclo Therapeutics, Inc. (CYTH) Reports Q3 Loss, Lags Revenue Estimates

Cyclo Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today reported its financial results for the third quarter 2024 and provided a business update. “The third quarter has been marked by important advancements on our clinical and corporate fronts. We are poised to comp.

Cyclo Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Cyclo Therapeutics Presents Encouraging Preliminary Safety Data from Ongoing Pivotal Phase 3 Study and Substudy for the Treatment of Niemann-Pick Disease Type C1 (NPC1)

GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced the presentation of positive preliminary data from its ongoing pivotal Phase 3 study (“TransportNPC™”) and substudy evaluating Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1 (NPC1).

Cyclo Therapeutics Presents Encouraging Preliminary Safety Data from Ongoing Pivotal Phase 3 Study and Substudy for the Treatment of Niemann-Pick Disease Type C1 (NPC1)

CYCLO THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Cyclo Therapeutics, Inc. - CYTH

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Cyclo Therapeutics, Inc. (the “Company”) (NasdaqCM: CYTH) and Rafael Holdings, Inc. (NYSE: RFL). KSF is seeking to determine whether the merger and the process that led to it are adequate, or whether the merger is fair to the Company's shareholders. If you would like to discuss your legal rights regarding th.

CYCLO THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Cyclo Therapeutics, Inc. - CYTH

Shareholder Alert: Ademi LLP investigates whether Cyclo Therapeutics, Inc. has obtained a Fair Price for its Public Shareholders

MILWAUKEE , Aug. 23, 2024 /PRNewswire/ -- Ademi LLP is investigating Cyclo Therapeutics (Nasdaq: CYTH) for possible breaches of fiduciary duty and other violations of law in its transaction with Rafael Holdings. Click here to learn how to join our investigation https://www.ademilaw.com/case/cyclo-therapeutics-inc or call Guri Ademi toll-free at 866-264-3995.

Shareholder Alert: Ademi LLP investigates whether Cyclo Therapeutics, Inc. has obtained a Fair Price for its Public Shareholders

SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Cyclo Therapeutics, Inc. - CYTH

NEW YORK , Aug. 22, 2024 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Cyclo Therapeutics, Inc. (Nasdaq: CYTH), relating to its proposed merger with Rafael Holdings, Inc. Under the terms of the agreement, Cyclo common stock will automatically be converted into the right to receive shares of Rafael common stock.

SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Cyclo Therapeutics, Inc. - CYTH

STOCKHOLDER ALERT: The M&A Class Action Firm Investigates the Mergers of VGR, CYTH

NEW YORK, NY / ACCESSWIRE / August 22, 2024 / Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating: Vector Group Ltd.

STOCKHOLDER ALERT: The M&A Class Action Firm Investigates the Mergers of VGR, CYTH

Accession Risk Management Group Closes $1 Billion Financing to Further Accelerate Growth of Risk Strategies and One80 Intermediaries

BOSTON--(BUSINESS WIRE)--Accession Risk Management Group, the parent company of Risk Strategies and One80 Intermediaries comprising North America's ninth largest privately held insurance broker, has closed a $1 billion incremental debt raise and refinancing. The funding will further accelerate a remarkable growth trajectory driven by the continued acquisition of leading specialty brokerages and targeted organic expansion. Accession Risk Management Group is a portfolio company of Kelso & Co.

Accession Risk Management Group Closes $1 Billion Financing to Further Accelerate Growth of Risk Strategies and One80 Intermediaries

Rafael Holdings and Cyclo Therapeutics Enter Into a Definitive Merger Agreement

NEWARK, N.J. & GAINESVILLE, Fla.--(BUSINESS WIRE)--Rafael Holdings, Inc. (NYSE: RFL), and Cyclo Therapeutics, Inc. (Nasdaq: CYTH) today announced that they have entered into a definitive merger agreement to combine the two companies to focus on the development of Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1. On consummation of the merger, Rafael Holdings will issue shares of its Class B common stock to Cyclo Therapeutics' shareholders, based on an exchange ratio valuing Cy.

Rafael Holdings and Cyclo Therapeutics Enter Into a Definitive Merger Agreement

Cyclo Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today reported its financial results for the second quarter 2024 and provided a business update. “The second quarter represents a transformative time for the Company with the achievement of a landmark milestone -- the.

Cyclo Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

See News Rankings

Charts implemented using Lightweight Charts™